30 & 60
Daklibiox is indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.
Dosage and Administration:
The recommended dosage of Daclatasvir is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. Daclatasvir may be taken with or without food. Reduce dosage to 30 mg once daily with strong CYP3A inhibitors and increase dosage to 90 mg once daily with moderate CYP3A inducers.
Daclatavir in combination with sofosbuvir: Most common adverse reactions (≥10%) observed were headache and fatigue and nausea.
Daclatasvir in combination with peginterferon alfa and ribavirin:The most frequently reported adverse reactions were fatigue, headache, pruritus, anaemia, influenza-like illness, nausea, insomnia, neutropenia, asthenia, rash, decreased appetite, dry skin, alopecia, pyrexia, myalgia, irritability, cough, diarrhoea, dyspnoea and arthralgia.